Category: News

We are proud to announce the official launch of the Egypt Pharmacometrics Chapter, a dedicated community of scientists, clinicians, and educators committed to advancing clinical pharmacology and model-informed drug development (MIDD) across Egypt, the Middle East, and Africa. Egypt now formally joins a growing continental network of national pharmacometrics chapters, united in the conviction that quantitative science can meaningfully transform the way medicines are developed, evaluated, and personalised for patients. The Egypt Pharmacometrics Chapter is part of the Pharmacometrics Africa network. We bring together researchers, clinical pharmacologists, pharmaceutical scientists, and educators from across Egypt who share a common ambition: to build a rigorous, inclusive, and impact-driven pharmacometrics community that can hold its own on the world stage. Our work is grounded in science and driven by a sense of regional responsibility, the belief that Egypt, sitting at the crossroads of the Middle East and Africa, is uniquely positioned to lead. Why Pharmacometrics Matters for Egypt, the Region, and the World Drug development has never been more quantitative. Across the globe, regulators, industry, and clinical scientists are turning to model-informed approaches such as pharmacometrics, population pharmacokinetic/pharmacodynamic modelling, physiologically based pharmacokinetic modelling, and systems pharmacology to make smarter, faster, and more ethical decisions about medicines. This shift is not a trend; it is a transformation, and it carries profound implications for countries like Egypt and the broader Middle East and Africa. MIDD represents a framework that integrates mathematical and computational models throughout the entire drug development lifecycle  from preclinical candidate selection and